Where does Vaccinex, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Vaccinex, Inc. ranks #7,643 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Vaccinex, Inc. hold?

Vaccinex, Inc. holds 43 US utility patents granted between 2015 and 2025, spanning 8 technology areas.

What is Vaccinex, Inc.'s Innovation Score?

Vaccinex, Inc. has an Innovation Score of 39.6 out of 100 (top 38% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Vaccinex, Inc. focus on?

Vaccinex, Inc.'s top technology area is C07K (Peptides) with 40 patents, ranking #239 of 3,615 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Vaccinex, Inc.'s patent grant rate increasing or decreasing?

Vaccinex, Inc.'s recent grant velocity is +0% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Vaccinex, Inc.'s patents?

Vaccinex, Inc.'s patents average 16.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Vaccinex, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Vaccinex, Inc.

USPTO PatentsView assignee record - 43 granted patents across 8 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Vaccinex ranks #7,643 of 49,997 tracked US assignees by granted-patent volume, with 43 patents across 8 technology areas.

#7,643
of 49,997 US assignees by volume: Top 38%
by Innovation Score (39.6/100): 16.5
avg claims per patent: +0%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R7643 · US Corporation #7,643 · 43 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-FLAT · BOOK-FULL

GRANTS-SMALL 43 grants
UPPER-Q #7,643/49,997
PHOTO-FINISH Unilumin Group
CPC-NARROW C07K · 8 areas
INNOV-THIN 39.6/100
CLAIMS-RICH 16.5 claims/avg
TYPE-USCORP US Corporation
VEL-FLAT +0% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Unilumin Group Co., Ltd (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Vaccinex’s 39.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.1 pts (33%) Velocity 6.7 pts (17%) Breadth 10.0 pts (25%) Claim depth 9.9 pts (25%)

Qualcomm Incorporated · highest

85
Natus Medical… · near

40
Palliare · near

40
PointSource · near

40
Taiwan FU Hsing… · near

40
Vaccinex · this assignee

40
3D Lighting… · lowest

7

What this shows Vaccinex's Innovation Score is 39.6/100 (top 38% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Vaccinex?

Each dot is one of Vaccinex’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Vaccinex’s own 16.5 claims/patent is ABOVE the 15.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Vaccinex vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Vaccinex's grants concentrate

Vaccinex, Inc. is a focused PatentsView assignee: 8 CPC subclasses with 93% of grants classified under C07K (Peptides). Peak complete grant year is 2017 (9 grants) versus a trough of 1 in 2015. By volume, Vaccinex sits between Unilumin Group Co., Ltd and WaveLight GmbH.

Vaccinex's three-year grant acceleration

Vaccinex, Inc. shows 12 grants in 2022–2024 against only 12 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Unilumin Group

43
University OF Day…

43
University OF Hou…

43
University of Nor…

43
Victoria's Secret…

43
Vonage America

43
Wake Forest Unive…

43
Wavelight

43
Vaccinex ◀

43

What this shows Vaccinex holds 43 patents at rank #7,643, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Vaccinex

By rank, the assignees closest to #7,643 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Vaccinex's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Vaccinex, neither rank-band nor same-CPC leaders (those blocks stay above). In C07K (Peptides), Vaccinex ranks #239 of 3,615 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (40 here).

Taiwan FU Hsing Industrial Co., Ltd. 40 Natus Medical Incorporated 40 PointSource Technologies, LLC 40 Palliare Limited 40

Vaccinex's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 38% higher than 62% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Vaccinex, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	2.3%
2016	5	11.6%
2017	9	20.9%
2018	3	7.0%
2019	3	7.0%
2020	8	18.6%
2021	1	2.3%
2022	3	7.0%
2023	3	7.0%
2024	6	14.0%
2025partial year	1	2.3%

Which technologies does Vaccinex, Inc. patent most?

C07K - Peptides 40

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 33

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 29

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 15

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 8

Y02A - Technologies FOR Adaptation TO Climate Change 6

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 5

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 2

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Vaccinex, Inc.'s patent record in context - here's where to go next.

Vaccinex, Inc.'s lead technology class is C07K (Peptides), 93% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #7,643 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Vaccinex, Inc. against Unilumin Group Co., Ltd, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 39.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.